Feasibility and benefits of reclaiming a man-made lake: A case study of Lake Paradise Mattoon, Illinois

Man-made lakes in Illinois and other states are experiencing severe sedimentation problems, which reduce water-storage capacities and degrade water quality, as well as limit recreational opportunities. In a pilot project at Lake Paradise, Mattoon, Illinois, a number of studies have been conducted on the feasibility and benefits of lake reclamation. Included are studies on the feasibility of dredging Lake Paradise, on the importance of recreation planning to lake reclamation, and on the economics of lake reclamation. The Lake Paradise studies indicate that the sediment of Lake Paradise can be dredged to increase storage capacity and improve water quality and that the sediment can probably be restored as a soil amendment to the surrounding farmland. The studies also indicate that recreation should be an important consideration of lake reclamation planning and that lake reclamation may be cost-efficient compared to other alternatives such as constructing additional water-supply reservoirs. It is recommended that Illinois communities that are experiencing problems with their lakes due to sediment suspension and accumulation should consider lake reclamation as one possible element of a water resources management program. In evaluating the potential of lake reclamation, communities should conduct studies to determine the feasibility of dredging and the uses of the dredged sediments, the economic benefits of reclamation as compared to other alternatives, and the perceptions that local residents have of the benefits of reclaiming a lake. It is also recommended that further research studies of the economics and techniques of dredging and sediment disposal be conducted.U.S. Department of the InteriorU.S. Geological SurveyOpe

Circadian Oscillations in the Murine Preoptic Area Are Reset by Temperature, but Not Light

Mammals maintain their internal body temperature within a physiologically optimal range. This involves the regulation of core body temperature in response to changing environmental temperatures and a natural circadian oscillation of internal temperatures. The preoptic area (POA) of the hypothalamus coordinates body temperature by responding to both external temperature cues and internal brain temperature. Here we describe an autonomous circadian clock system in the murine ventromedial POA (VMPO) in close proximity to cells which express the atypical violet-light sensitive opsin, Opn5. We analyzed the light-sensitivity and thermal-sensitivity of the VMPO circadian clocks ex vivo. The phase of the VMPO circadian oscillations was not influenced by light. However, the VMPO clocks were reset by temperature changes within the physiological internal temperature range. This thermal-sensitivity of the VMPO circadian clock did not require functional Opn5 expression or a functional circadian clock within the Opn5-expressing cells. The presence of temperature-sensitive circadian clocks in the VMPO provides an advancement in the understanding of mechanisms involved in the dynamic regulation of core body temperature

Opening and Closing Jaw Movements of Young Children who Stutter.

Objective: In this longitudinal study, we investigated the hypothesis that kinematic measures of jaw movement produced by children who stuttered (CWS) and children who did not stutter (CWNS) would differ between opening and closing speech gestures, across phonetic contexts, and across development. Methods: Mean amplitude, velocity, and duration of jaw opening and closing gestures during repeated productions of bilabial syllables were analyzed longitudinally at 1-year intervals for 13 CWS and 7 children CWNS. The utterances ranged across four phonetic contexts: single-syllable, two-syllable, three-syllable, and six-syllable. For jaw movement transduction, a strain gauge was attached to a football helmet in a novel design to minimize head movement. All kinematic measures were made from jaw movement tracings in Windaq (Dataq Instruments, Inc.) software, based on a standard millimeter to voltage conversion. Results: The main finding of the study was that opening gestures were produced by both CWS and CWNS with greater amplitude and duration compared to closing gestures. However, the kinematics associated with opening and closing jaw movements did not differ between CWS and CWNS, suggesting that the intrinsic articulatory dynamics of the two groups were similar. In addition, adapting the kinematics of opening and closing jaw movements across the four phonetic contexts did not differ between the groups for either movement amplitude or velocity. However, CWS produced the closing gesture with significantly greater duration compared to multi-syllable conditions, relative to CWNS. Finally, CWS and CWNS exhibited different longitudinal patterns for jaw amplitude and peak velocity. Conclusion: The speech motor systems of CWS and CWNS exhibited broadly similar organization of intrinsic articulatory dynamics, but groups may differ in how underlying dynamics are adapted to changing phonetic contexts across development. It is possible that the speech fluency of CWS might benefit from greater articulatory constraints, as the main between-group difference was identified when degrees of freedom of movement were greatest. Implications of findings are discussed within the development of a hierarchically organized speech motor system

Measuring soot particles from automotive exhaust emissions

The European Metrology Research Programme participating countries and the European Union jointly fund a three year project to address the need of the automotive industry for a metrological sound base for exhaust measurements. The collaborative work on particle emissions involves five European National Metrology Institutes, the Tampere University of Technology, the Joint Research Centre for Energy and Transport and the Leibniz Institute for Tropospheric Research. On one hand, a particle number and size standard for soot particles is aimed for. Eventually this will allow the partners to provide accurate and comparable calibrations of measurement instruments for the type approval of Euro 5b and Euro 6 vehicles. Calibration aerosols of combustion particles, silver and graphite proof partially suitable. Yet, a consensus choice together with instrument manufactures is pending as the aerosol choice considerably affects the number concentration measurement. Furthermore, the consortium issued consistent requirements for novel measuring instruments foreseen to replace today’s opacimeters in regulatory periodic emission controls of soot and compared them with European legislative requirements. Four partners are conducting a metrological validation of prototype measurement instruments. The novel instruments base on light scattering, electrical, ionisation chamber and diffusion charging sensors and will be tested at low and high particle concentrations. Results shall allow manufacturers to further improve their instruments to comply with legal requirements

Clinical Significance of Bronchodilator Responsiveness Evaluated by Forced Vital Capacity in COPD: SPIROMICS Cohort Analysis.

ObjectiveBronchodilator responsiveness (BDR) is prevalent in COPD, but its clinical implications remain unclear. We explored the significance of BDR, defined by post-bronchodilator change in FEV1 (BDRFEV1) as a measure reflecting the change in flow and in FVC (BDRFVC) reflecting the change in volume.MethodsWe analyzed 2974 participants from a multicenter observational study designed to identify varying COPD phenotypes (SPIROMICS). We evaluated the association of BDR with baseline clinical characteristics, rate of prospective exacerbations and mortality using negative binomial regression and Cox proportional hazards models.ResultsA majority of COPD participants exhibited BDR (52.7%). BDRFEV1 occurred more often in earlier stages of COPD, while BDRFVC occurred more frequently in more advanced disease. When defined by increases in either FEV1 or FVC, BDR was associated with a self-reported history of asthma, but not with blood eosinophil counts. BDRFVC was more prevalent in subjects with greater emphysema and small airway disease on CT. In a univariate analysis, BDRFVC was associated with increased exacerbations and mortality, although no significance was found in a model adjusted for post-bronchodilator FEV1.ConclusionWith advanced airflow obstruction in COPD, BDRFVC is more prevalent in comparison to BDRFEV1 and correlates with the extent of emphysema and degree of small airway disease. Since these associations appear to be related to the impairment of FEV1, BDRFVC itself does not define a distinct phenotype nor can it be more predictive of outcomes, but it can offer additional insights into the pathophysiologic mechanism in advanced COPD.Clinical trials registrationClinicalTrials.gov: NCT01969344T4

Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.

Importance: Evidence regarding corticosteroid use for severe coronavirus disease 2019 (COVID-19) is limited. Objective: To determine whether hydrocortisone improves outcome for patients with severe COVID-19. Design, Setting, and Participants: An ongoing adaptive platform trial testing multiple interventions within multiple therapeutic domains, for example, antiviral agents, corticosteroids, or immunoglobulin. Between March 9 and June 17, 2020, 614 adult patients with suspected or confirmed COVID-19 were enrolled and randomized within at least 1 domain following admission to an intensive care unit (ICU) for respiratory or cardiovascular organ support at 121 sites in 8 countries. Of these, 403 were randomized to open-label interventions within the corticosteroid domain. The domain was halted after results from another trial were released. Follow-up ended August 12, 2020. Interventions: The corticosteroid domain randomized participants to a fixed 7-day course of intravenous hydrocortisone (50 mg or 100 mg every 6 hours) (n = 143), a shock-dependent course (50 mg every 6 hours when shock was clinically evident) (n = 152), or no hydrocortisone (n = 108). Main Outcomes and Measures: The primary end point was organ support-free days (days alive and free of ICU-based respiratory or cardiovascular support) within 21 days, where patients who died were assigned -1 day. The primary analysis was a bayesian cumulative logistic model that included all patients enrolled with severe COVID-19, adjusting for age, sex, site, region, time, assignment to interventions within other domains, and domain and intervention eligibility. Superiority was defined as the posterior probability of an odds ratio greater than 1 (threshold for trial conclusion of superiority >99%). Results: After excluding 19 participants who withdrew consent, there were 384 patients (mean age, 60 years; 29% female) randomized to the fixed-dose (n = 137), shock-dependent (n = 146), and no (n = 101) hydrocortisone groups; 379 (99%) completed the study and were included in the analysis. The mean age for the 3 groups ranged between 59.5 and 60.4 years; most patients were male (range, 70.6%-71.5%); mean body mass index ranged between 29.7 and 30.9; and patients receiving mechanical ventilation ranged between 50.0% and 63.5%. For the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively, the median organ support-free days were 0 (IQR, -1 to 15), 0 (IQR, -1 to 13), and 0 (-1 to 11) days (composed of 30%, 26%, and 33% mortality rates and 11.5, 9.5, and 6 median organ support-free days among survivors). The median adjusted odds ratio and bayesian probability of superiority were 1.43 (95% credible interval, 0.91-2.27) and 93% for fixed-dose hydrocortisone, respectively, and were 1.22 (95% credible interval, 0.76-1.94) and 80% for shock-dependent hydrocortisone compared with no hydrocortisone. Serious adverse events were reported in 4 (3%), 5 (3%), and 1 (1%) patients in the fixed-dose, shock-dependent, and no hydrocortisone groups, respectively. Conclusions and Relevance: Among patients with severe COVID-19, treatment with a 7-day fixed-dose course of hydrocortisone or shock-dependent dosing of hydrocortisone, compared with no hydrocortisone, resulted in 93% and 80% probabilities of superiority with regard to the odds of improvement in organ support-free days within 21 days. However, the trial was stopped early and no treatment strategy met prespecified criteria for statistical superiority, precluding definitive conclusions. Trial Registration: ClinicalTrials.gov Identifier: NCT02735707

The reference site collaborative network of the european innovation partnership on active and healthy ageing

Seventy four Reference Sites of the European Innovation Partnership on Active and Healthy Ageing (EIP on AHA) have been recognised by the European Commission in 2016 for their commitment to excellence in investing and scaling up innovative solutions for active and healthy ageing. The Reference Site Collaborative Network (RSCN) brings together the EIP on AHA Reference Sites awarded by the European Commission, and Candidate Reference Sites into a single forum. The overarching goals are to promote cooperation, share and transfer good practice and solutions in the development and scaling up of health and care strategies, policies and service delivery models, while at the same time supporting the action groups in their work. The RSCN aspires to be recognized by the EU Commission as the principal forum and authority representing all EIP on AHA Reference Sites. The RSCN will contribute to achieve the goals of the EIP on AHA by improving health and care outcomes for citizens across Europe, and the development of sustainable economic growth and the creation of jobs

Effect of angiotensin-converting enzyme inhibitor and angiotensin receptor blocker initiation on organ support-free days in patients hospitalized with COVID-19

IMPORTANCE Overactivation of the renin-angiotensin system (RAS) may contribute to poor clinical outcomes in patients with COVID-19. Objective To determine whether angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB) initiation improves outcomes in patients hospitalized for COVID-19. DESIGN, SETTING, AND PARTICIPANTS In an ongoing, adaptive platform randomized clinical trial, 721 critically ill and 58 non–critically ill hospitalized adults were randomized to receive an RAS inhibitor or control between March 16, 2021, and February 25, 2022, at 69 sites in 7 countries (final follow-up on June 1, 2022). INTERVENTIONS Patients were randomized to receive open-label initiation of an ACE inhibitor (n = 257), ARB (n = 248), ARB in combination with DMX-200 (a chemokine receptor-2 inhibitor; n = 10), or no RAS inhibitor (control; n = 264) for up to 10 days. MAIN OUTCOMES AND MEASURES The primary outcome was organ support–free days, a composite of hospital survival and days alive without cardiovascular or respiratory organ support through 21 days. The primary analysis was a bayesian cumulative logistic model. Odds ratios (ORs) greater than 1 represent improved outcomes. RESULTS On February 25, 2022, enrollment was discontinued due to safety concerns. Among 679 critically ill patients with available primary outcome data, the median age was 56 years and 239 participants (35.2%) were women. Median (IQR) organ support–free days among critically ill patients was 10 (–1 to 16) in the ACE inhibitor group (n = 231), 8 (–1 to 17) in the ARB group (n = 217), and 12 (0 to 17) in the control group (n = 231) (median adjusted odds ratios of 0.77 [95% bayesian credible interval, 0.58-1.06] for improvement for ACE inhibitor and 0.76 [95% credible interval, 0.56-1.05] for ARB compared with control). The posterior probabilities that ACE inhibitors and ARBs worsened organ support–free days compared with control were 94.9% and 95.4%, respectively. Hospital survival occurred in 166 of 231 critically ill participants (71.9%) in the ACE inhibitor group, 152 of 217 (70.0%) in the ARB group, and 182 of 231 (78.8%) in the control group (posterior probabilities that ACE inhibitor and ARB worsened hospital survival compared with control were 95.3% and 98.1%, respectively). CONCLUSIONS AND RELEVANCE In this trial, among critically ill adults with COVID-19, initiation of an ACE inhibitor or ARB did not improve, and likely worsened, clinical outcomes. TRIAL REGISTRATION ClinicalTrials.gov Identifier: NCT0273570

An investigation of artificial neural networks applied to pairs trading in South Africa

The use of artificial intelligence models could enhance the process by which decisions are made for trading in the financial markets. In this project the aim was to define, create, apply and analyse the results of an artificial neural network based solution for so-called pairs trading. A literature study is presented where a brief summary is given of the current body of knowl- edge with regards to artificial neural networks and their application in finance. Additionally an introduction of the software packages used in this project is given. In a separate chapter a short introduction on trading strategies and pairs trading, specifically, is included. The design of the artificial neural network is discussed in detail with both training and execu- tion results from experiments critically examined. Finally the question ‘Are artificial neural networks a viable tool applied to pairs trading in the South African market?’ is answered based on the empirical evidence.Dissertation (MSc)--University of Pretoria, 2014.lk2014Materials Science and Metallurgical EngineeringMScUnrestricte

Feature recognition in 3D surface models using self-organizing maps

M.Ing.This project investigates the use of Self-Organizing Maps (SOM) for feature recognition and analysis in 3D objects. Object data was generated to simulate data obtained from 3D scanning and trained using SOM. The trained data was analysed using speci cally developed software. The feature recognition and analysis process can be summarized as follows: a 3D object le is converted to a pure 3D data le, this data le is trained using the SOM algorithm after which the output is analyzed using a 3D object viewer and SOM data display